In July 2020, the U.S. Food and Drug Administration granted accelerated approval of Monjuvi® (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. We are very proud that we could bring a new treatment option to thousands of patients and are a commercial-stage biopharma company now.
In 2017, Tremfya® (guselkumab) became the first drug based on MorphoSys' antibody technology to receive regulatory approval. Today, the blockbuster drug is approved for both plaque psoriasis and psoriatic arthritis in the US and Europe, and several other countries. Janssen Research & Development, LLC is running a broad clinical development program for guselkumab in various indications, including Crohn's disease and Ulcerative colitis. Tremfya® is marketed by Janssen Biotech, Inc.
Being able to help patients, give them hope and provide them with the best treatment available is the strongest motivation driving our more than 750 employees across Germany and the United States. As of July 15, 2021, Constellation Pharmaceuticals is a MorphoSys company. Together, we come to work every day, driven to make a difference.
Open and complete information is a guiding principle for the cooperation of MorphoSys’ Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their commitment objective is the sustainable increase in the company’s value.